Nosrati, Adi
Tsai, Katy K
Goldinger, Simone M
Tumeh, Paul
Grimes, Barbara
Loo, Kimberly
Algazi, Alain P
Nguyen-Kim, Thi Dan Linh
Levesque, Mitchell
Dummer, Reinhard
Hamid, Omid
Daud, Adil
Article History
Received: 19 October 2016
Revised: 22 February 2017
Accepted: 28 February 2017
First Online: 21 March 2017
Competing interests
: SMG: Research funding from the Zurich University Hospital and received travel grant support from Novartis, Roche, MSD and BMS. He has an intermittent advisory board relationship with Novartis, Roche, MSD and BMS. PT: Founder and employee at Acteris. APA: Grants for clinical trial support from Merck, Bristol-Myers Squibb (BMS), Medimmune, AstraZeneca, Oncosec, Acerta, Novartis, and Glaxco SmithKline. RD: Research funding (Novartis, Merck and Co., Inc., Bristol-Myers Squibb, Roche, GlaxoSmithKline) and consultancy or advisory board (Novartis, Merck and Co., Inc., Bristol-Myers Squibb, Roche, GlaxoSmithKline, Amgen). OH: Consultancy (Amgen, Novartis, Roche, Bristol-Myers Squibb) and speaker (Bristol-Myers Squibb, Genentech, Novartis). AD: Advisory board: Merck Inc., Pfizer Inc., BMS Inc., Novartis, and Genentech Roche. Stock: OncoSec Inc. The other authors declare no conflict of interest.